


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Gerritsen <i>et al.</i></p> <p>Serial No.: not assigned</p> <p>Filed: October 5, 2000</p> <p>For: NOVEL POLYPEPTIDES, THEIR NUCLEIC ACIDS, AND METHODS FOR THEIR USE IN ANGIOGENESIS AND VASCULARIZATION</p>	<p>Group Art Unit: unassigned</p> <p>Examiner: unassigned</p> <hr/> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Director of Patents and Trademarks, Washington, DC 20231 on</p> <p>October 5, 2000</p> <p> Glory L. Tabuena</p>
---	--

CERTIFICATE RE: SEQUENCE LISTING
RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Box Sequence
Director of Patents and Trademarks
Washington, DC 20231


Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: October 5, 2000

By: 
Timothy R. Schwartz, Ph.D.
Reg. No. 32,171

1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881